BUZZ-Cognition Therapeutics rises as dementia drug meets main goal in mid-stage trial

Reuters12-18
BUZZ-Cognition <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises as dementia drug meets main goal in mid-stage trial

** Shares of Cognition Therapeutics CGTX.O rise 76.7% to 81 cents premarket

** Drug developer says its experimental oral drug, CT1812, met the main goal of safety and tolerability in a mid-stage study

** The study enrolled 130 patients with mild-to-moderate dementia with Lewy bodies - a type of dementia that affects thinking, movement, behavior, and mood

** Co says "patients treated with CT1812 for six months experienced improvement in behavioral, functional, cognitive and movement measures compared to placebo"

** Adds, "there was a marked reduction in caregiver distress, which suggests a positive impact on the day-to-day lives of those receiving the drug"

** Says detailed data will be presented at a medical conference in January 2025

** Says expediting plans to advance CT1812 into late-stage trials

** Up to last close, stock down 75.4% YTD

(Reporting by Sneha S K in Bengaluru)

((Sneha.SK@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment